Evaluation of association of HLA alleles with hepatotoxicity in patients receiving abemaciclib (confirmatory study)

Evaluation of association of HLA alleles with hepatotoxicity in patients receiving abemaciclib (confirmatory study) - Evaluation of association of HLA alleles with hepatotoxicity in patients receiving abemaciclib (confirmatory study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000054091

Enrollment

120

Registered

2024-04-08

Start date

2024-04-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Breast cancer patients receiving abemaciclib for more than 90 days.

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
To assess the association of HLA alleles with abemaciclib-induced hepatotoxicity	—

Secondary

Measure	Time frame
nothing	—

Countries

Japan

Contacts

Public ContactChiyo Imamura

Showa University Advanced Cancer Translational Research Institute

imamurack@med.showa-u.ac.jp03-3784-8146

Outcome results